Pan‑cancer analysis of the deoxyribonuclease gene family

Bai,Qingquan; He,Xiao; Hu,Tianhui

doi:10.3892/mco.2023.2615

Pan‑cancer analysis of the deoxyribonuclease gene family

Authors:
- Qingquan Bai
- Xiao He
- Tianhui Hu
View Affiliations

Affiliations: Department of Hepatology and Gastroenterology, Campus Virchow Clinic and Campus Charité Mitte, Charité University Medicine, D‑13353 Berlin, Germany, Department of Neurology, The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong 250014, P.R. China, Cancer Research Center, School of Medicine, Xiamen University, Xiamen, Fujian 361102, P.R. China
Published online on: February 2, 2023 https://doi.org/10.3892/mco.2023.2615
Article Number: 19
Copyright: © Bai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Deoxyribonuclease (DNase) is an enzyme that catalyzes the cleavage of phosphodiester bonds in the main chain of DNA to degrade DNA. DNase serves a vital role in several immune‑related diseases. The present study linked the expression of DNase with overall survival (OS), performed pan‑cancer co‑expression analysis, and assessed the association between DNase and immune infiltration subtypes, tumor microenvironment and drug sensitivity through pan‑cancer studies. Furthermore, gene expression data and clinical data were downloaded from The Cancer Genome Atlas. Next, through a series of bioinformatics analyses, DNase expression and survival, immune subtypes, tumor microenvironment and drug sensitivity in 33 tumor types were systematically studied. The expression of the DNase gene family was shown to have an apparent intratumoral heterogeneity. The expression of DNase 2, lysosomal (DNASE2) was the highest in tumors, whereas that of DNASE2 β was the lowest. DNase 1‑like 3 (DNASE1L3) was mainly downregulated in tumors, whereas the rest of the DNases were mainly upregulated in tumors. The expression of DNase family members was also found to be associated with the OS rate of patients. DNase family genes may serve an essential role in the tumor microenvironment. DNase family gene expression was related to the content of cytotoxic cells, Immunescore, Stromalscore, Estimatescore and Tumorpurity. The present study also revealed that the DNase genes may be involved in the drug resistance of cancer cells. Finally, the correlation between DNase, and clinical stage and tumor microenvironment in hepatocellular carcinoma (HCC) was studied. In addition, the difference in DNASE1L3 expression between HCC and adjacent normal tissues, and the relationship between DNASE1L3 expression and clinical stage was verified by analyzing three groups in a Gene Expression Omnibus dataset and by performing immunohistochemistry. In conclusion, the present study assessed DNase gene expression, analyzed its relationship with patient OS, performed pan‑cancer co‑expression analysis, and assessed the association between DNase and immune infiltration subtypes, tumor microenvironment and drug sensitivity. The present study also confirmed the value of further laboratory research on DNases and their prospects in clinical cancer treatment.

View Figures

View References

1	Keyel PA: Dnases in health and disease. Dev Biol. 429:1–11. 2017.PubMed/NCBI View Article : Google Scholar
2	Yasutomo K, Horiuchi T, Kagami S, Tsukamoto H, Hashimura C, Urushihara M and Kuroda Y: Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet. 28:313–314. 2001.PubMed/NCBI View Article : Google Scholar
3	Bodaño A, Amarelo J, González A, Gómez-Reino JJ and Conde C: Novel DNASE I mutations related to systemic lupus erythematosus. Arthritis Rheum. 50:4070–4071. 2004.PubMed/NCBI View Article : Google Scholar
4	Frost PG and Lachmann PJ: The relationship of desoxyribonuclease inhibitor levels in human sera to the occurrence of antinuclear antibodies. Clin Exp Immunol. 3:447–455. 1968.PubMed/NCBI
5	Tew MB, Johnson RW, Reveille JD and Tan FK: A molecular analysis of the low serum deoxyribonuclease activity in lupus patients. Arthritis Rheum. 44:2446–2447. 2001.PubMed/NCBI View Article : Google Scholar
6	Sallai K, Nagy E, Derfalvy B, Müzes G and Gergely P: Antinucleosome antibodies and decreased deoxyribonuclease activity in sera of patients with systemic lupus erythematosus. Clin Diagn Lab Immunol. 12:56–59. 2005.PubMed/NCBI View Article : Google Scholar
7	Hakkim A, Fürnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, Herrmann M, Voll RE and Zychlinsky A: Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA. 107:9813–9818. 2010.PubMed/NCBI View Article : Google Scholar
8	Parrish JE, Ciccodicola A, Wehhert M, Cox GF, Chen E and Nelson DL: A muscle-specific DNase I-like gene in human Xq28. Hum Mol Genet. 4:1557–1564. 1995.PubMed/NCBI View Article : Google Scholar
9	Los M, Neubüser D, Coy JF, Mozoluk M, Poustka A and Schulze-Osthoff K: Functional characterization of DNase X, a novel endonuclease expressed in muscle cells. Biochemistry. 39:7365–7373. 2000.PubMed/NCBI View Article : Google Scholar
10	Shiokawa D and Tanuma S: Characterization of human DNase I family endonucleases and activation of DNase gamma during apoptosis. Biochemistry. 40:143–152. 2001.PubMed/NCBI View Article : Google Scholar
11	Shiokawa D, Shika Y, Saito K, Yamazaki K and Tanuma S: Physical and biochemical properties of mammalian DNase X proteins: Non-AUG translation initiation of porcine and bovine mRNAs for DNase X. Biochem J. 392:511–517. 2005.PubMed/NCBI View Article : Google Scholar
12	Shiokawa D, Matsushita T, Shika Y, Shimizu M, Maeda M and Tanuma S: DNase X is a glycosylphosphatidylinositol-anchored membrane enzyme that provides a barrier to endocytosis-mediated transfer of a foreign gene. J Biol Chem. 282:17132–17140. 2007.PubMed/NCBI View Article : Google Scholar
13	Malferrari G, Mazza U, Tresoldi C, Rovida E, Nissim M, Mirabella M, Servidei S and Biunno I: Molecular characterization of a novel endonuclease (Xib) and possible involvement in lysosomal glycogen storage disorders. Exp Mol Pathol. 66:123–130. 1999.PubMed/NCBI View Article : Google Scholar
14	Malferrari G, Mirabella M, D'Alessandra Y, Servidei S and Biunno I: Deletion polymorphism of DNASE1L1, an X-linked DNase I-like gene, in acid maltase deficiency disorders. Exp Mol Pathol. 70:173–174. 2001.PubMed/NCBI View Article : Google Scholar
15	Fischer H, Eckhart L, Mildner M, Jaeger K, Buchberger M, Ghannadan M and Tschachler E: DNase1L2 degrades nuclear DNA during corneocyte formation. J Invest Dermatol. 127:24–30. 2007.PubMed/NCBI View Article : Google Scholar
16	Fischer H, Szabo S, Scherz J, Jaeger K, Rossiter H, Buchberger M, Ghannadan M, Hermann M, Theussl HC, Tobin DJ, et al: Essential role of the keratinocyte-specific endonuclease DNase1L2 in the removal of nuclear DNA from hair and nails. J Invest Dermatol. 131:1208–1215. 2011.PubMed/NCBI View Article : Google Scholar
17	Napirei M, Ricken A, Eulitz D, Knoop H and Mannherz HG: Expression pattern of the deoxyribonuclease 1 gene: Lessons from the Dnase1 knockout mouse. Biochem J. 380:929–937. 2004.PubMed/NCBI View Article : Google Scholar
18	Peitsch MC, Irmler M, French LE and Tschopp J: Genomic organisation and expression of mouse deoxyribonuclease I. Biochem Biophys Res Commun. 207:62–68. 1995.PubMed/NCBI View Article : Google Scholar
19	Napirei M, Ludwig S, Mezrhab J, Klöckl T and Mannherz HG: Murine serum nucleases-contrasting effects of plasmin and heparin on the activities of DNase1 and DNase1-like 3 (DNase1l3). FEBS J. 276:1059–1073. 2009.PubMed/NCBI View Article : Google Scholar
20	Boulares AH, Zoltoski AJ, Contreras FJ, Yakovlev AG, Yoshihara K and Smulson ME: Regulation of DNAS1L3 endonuclease activity by poly(ADP-ribosyl)ation during etoposide-induced apoptosis. Role of poly(ADP-ribose) polymerase-1 cleavage in endonuclease activation. J Biol Chem. 277:372–378. 2002.PubMed/NCBI View Article : Google Scholar
21	Liu QY, Lei JX, LeBlanc J, Sodja C, Ly D, Charlebois C, Walker PR, Yamada T, Hirohashi S and Sikorska M: Regulation of DNaseY activity by actinin-alpha4 during apoptosis. Cell Death Differ. 11:645–654. 2004.PubMed/NCBI View Article : Google Scholar
22	Shiokawa D, Kobayashi T and Tanuma S: Involvement of DNase gamma in apoptosis associated with myogenic differentiation of C2C12 cells. J Biol Chem. 277:31031–31037. 2002.PubMed/NCBI View Article : Google Scholar
23	Mizuta R, Araki S, Furukawa M, Furukawa Y, Ebara S, Shiokawa D, Hayashi K, Tanuma S and Kitamura D: DNase γ is the effector endonuclease for internucleosomal DNA fragmentation in necrosis. PLoS One. 8(e80223)2013.PubMed/NCBI View Article : Google Scholar
24	Shiokawa D, Tanaka M, Kimura T, Hashizume K, Takasawa R, Ohyama H, Fujita K, Yamada T and Tanuma S: Characterization of two DNase gamma-specific monoclonal antibodies and the in situ detection of DNase gamma in the nuclei of apoptotic rat thymocytes. Biochem Biophys Res Commun. 275:343–349. 2000.PubMed/NCBI View Article : Google Scholar
25	Higami Y, Tsuchiya T, To K, Chiba T, Yamaza H, Shiokawa D, Tanuma S and Shimokawa I: Expression of DNase gamma during Fas-independent apoptotic DNA fragmentation in rodent hepatocytes. Cell Tissue Res. 316:403–407. 2004.PubMed/NCBI View Article : Google Scholar
26	Xiao Y, Yang K, Liu P, Ma D, Lei P and Liu Q: Deoxyribonuclease 1-like 3 inhibits hepatocellular carcinoma progression by inducing apoptosis and reprogramming glucose metabolism. Int J Biol Sci. 18:82–95. 2022.PubMed/NCBI View Article : Google Scholar
27	Deng Z, Xiao M, Du D, Luo N, Liu D, Liu T, Lian D and Peng J: DNASE1L3 as a prognostic biomarker associated with immune cell infiltration in cancer. Onco Targets Ther. 14:2003–2017. 2021.PubMed/NCBI View Article : Google Scholar
28	Li B, Ge Y, Yan W, Gong B, Cao K, Zhao R, Li C, Zhang Y, Jiang Y and Zuo S: DNASE1L3 inhibits proliferation, invasion and metastasis of hepatocellular carcinoma by interacting with β-catenin to promote its ubiquitin degradation pathway. Cell Prolif. 55(e13273)2022.PubMed/NCBI View Article : Google Scholar
29	Al-Mayouf SM, Sunker A, Abdwani R, Abrawi SA, Almurshedi F, Alhashmi N, Al Sonbul A, Sewairi W, Qari A, Abdallah E, et al: Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus. Nat Genet. 43:1186–118. 2011.PubMed/NCBI View Article : Google Scholar
30	Zochling J, Newell F, Charlesworth JC, Leo P, Stankovich J, Cortes A, Zhou Y, Stevens W, Sahhar J, Roddy J, et al: An Immunochip-based interrogation of scleroderma susceptibility variants identifies a novel association at DNASE1L3. Arthritis Res Ther. 16(438)2014.PubMed/NCBI View Article : Google Scholar
31	Ozçakar ZB, Foster J II, Diaz-Horta O, Kasapcopur O, Fan YS, Yalçınkaya F and Tekin M: DNASE1L3 mutations in hypocomplementemic urticarial vasculitis syndrome. Arthritis Rheum. 65:2183–2189. 2013.PubMed/NCBI View Article : Google Scholar
32	Odaka C and Mizuochi T: Role of macrophage lysosomal enzymes in the degradation of nucleosomes of apoptotic cells. J Immunol. 163:5346–5352. 1999.PubMed/NCBI
33	Fischer H, Scherz J, Szabo S, Mildner M, Benarafa C, Torriglia A, Tschachler E and Eckhart L: DNase 2 is the main DNA-degrading enzyme of the stratum corneum. PLoS One. 6(e17581)2011.PubMed/NCBI View Article : Google Scholar
34	Kawane K, Fukuyama H, Kondoh G, Takeda J, Ohsawa Y, Uchiyama Y and Nagata S: Requirement of DNase II for definitive erythropoiesis in the mouse fetal liver. Science. 292:1546–1549. 2001.PubMed/NCBI View Article : Google Scholar
35	Yoshida H, Okabe Y, Kawane K, Fukuyama H and Nagata S: Lethal anemia caused by interferon-beta produced in mouse embryos carrying undigested DNA. Nat Immunol. 6:49–56. 2005.PubMed/NCBI View Article : Google Scholar
36	Kawane K, Ohtani M, Miwa K, Kizawa T, Kanbara Y, Yoshioka Y, Yoshikawa H and Nagata S: Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages. Nature. 443:998–1002. 2006.PubMed/NCBI View Article : Google Scholar
37	Shiokawa D and Tanuma S: DLAD, a novel mammalian divalent cation-independent endonuclease with homology to DNase II. Nucleic Acids Res. 27:4083–4089. 1999.PubMed/NCBI View Article : Google Scholar
38	Krieser RJ, MacLea KS, Park JP and Eastman A: The cloning, genomic structure, localization, and expression of human deoxyribonuclease IIbeta. Gene. 269:205–216. 2001.PubMed/NCBI View Article : Google Scholar
39	Nishimoto S, Kawane K, Watanabe-Fukunaga R, Fukuyama H, Ohsawa Y, Uchiyama Y, Hashida N, Ohguro N, Tano Y, Morimoto T, et al: Nuclear cataract caused by a lack of DNA degradation in the mouse eye lens. Nature. 424:1071–1074. 2003.PubMed/NCBI View Article : Google Scholar
40	Siddam AD, Gautier-Courteille C, Perez-Campos L, Anand D, Kakrana A, Dang CA, Legagneux V, Méreau A, Viet J, Gross JM, et al: The RNA-binding protein Celf1 post-transcriptionally regulates p27Kip1 and Dnase2b to control fiber cell nuclear degradation in lens development. PLoS Genet. 14(e1007278)2018.PubMed/NCBI View Article : Google Scholar
41	From the American Association of Neurological Surgeons (AANS), American Society of Neuroradiology (ASNR), Cardiovascular and Interventional Radiology Society of Europe (CIRSE), Canadian Interventional Radiology Association (CIRA), Congress of Neurological Surgeons (CNS), European Society of Minimally Invasive Neurological Therapy (ESMINT), European Society of Neuroradiology (ESNR), European Stroke Organization (ESO), Society for Cardiovascular Angiography and Interventions (SCAI), Society of Interventional Radiology (SIR) et al. Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke. Int J Stroke. 13:612–632. 2018.PubMed/NCBI View Article : Google Scholar
42	Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, et al: The immune landscape of cancer. Immunity. 48:812–830.e14. 2014.
43	Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA, et al: Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 4(2612)2013.PubMed/NCBI View Article : Google Scholar
44	Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, Kamińska B, Huelsken J, Omberg L, Gevaert O, et al: Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell. 173:338–354.e15. 2018.PubMed/NCBI View Article : Google Scholar
45	Tamborero D, Rubio-Perez C, Muiños F, Sabarinathan R, Piulats JM, Muntasell A, Dienstmann R, Lopez-Bigas N and Gonzalez-Perez A: A Pan-cancer landscape of interactions between solid tumors and infiltrating immune cell populations. Clin Cancer Res. 24:3717–3728. 2018.PubMed/NCBI View Article : Google Scholar
46	Counis MF and Torriglia A: Acid DNases and their interest among apoptotic endonucleases. Biochimie. 88:1851–1858. 2006.PubMed/NCBI View Article : Google Scholar
47	Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H and Trajanoski Z: Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 18:248–262. 2017.PubMed/NCBI View Article : Google Scholar
48	Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautès-Fridman C, Ma Y, Tartour E, Zitvogel L, et al: Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology. 1:1323–1343. 2012.PubMed/NCBI View Article : Google Scholar
49	Bi KW, Wei XG, Qin XX and Li B: BTK has potential to be a prognostic factor for lung adenocarcinoma and an indicator for tumor microenvironment remodeling: A study based on TCGA data mining. Front Oncol. 10(424)2020.PubMed/NCBI View Article : Google Scholar
50	Wood SL, Pernemalm M, Crosbie PA and Whetton AD: The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev. 40:558–566. 2014.PubMed/NCBI View Article : Google Scholar
51	Quail DF and Joyce JA: Microenvironmental regulation of tumor progression and metastasis. Nat Med. 19:1423–1437. 2013.PubMed/NCBI View Article : Google Scholar
52	Friedmann-Morvinski D and Verma IM: Dedifferentiation and reprogramming: Origins of cancer stem cells. EMBO Rep. 15:244–253. 2014.PubMed/NCBI View Article : Google Scholar
53	Ge Y, Gomez NC, Adam RC, Nikolova M, Yang H, Verma A, Lu CP, Polak L, Yuan S, Elemento O and Fuchs E: Stem cell lineage infidelity drives wound repair and cancer. Cell. 169:636–650.e14. 2017.PubMed/NCBI View Article : Google Scholar
54	Shibue T and Weinberg RA: EMT, CSCs, and drug resistance: The mechanistic link and clinical implications. Nat Rev Clin Oncol. 14:611–629. 2017.PubMed/NCBI View Article : Google Scholar
55	Visvader JE and Lindeman GJ: Cancer Stem cells: Current status and evolving complexities. Cell Stem Cell. 10:717–728. 2012.PubMed/NCBI View Article : Google Scholar